Nigel J Garrett
Overview
Explore the profile of Nigel J Garrett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1546
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scheepers C, Kgagudi P, Mzindle N, Gray E, Moyo-Gwete T, Lambson B, et al.
PLoS Pathog
. 2022 Sep;
18(9):e1010450.
PMID: 36054228
Broadly neutralizing antibodies (bNAbs) that target the membrane-proximal external region (MPER) of HIV gp41 envelope, such as 4E10, VRC42.01 and PGZL1, can neutralize >80% of viruses. These three MPER-directed monoclonal...
2.
Ngcobo S, Molatlhegi R, Osman F, Ngcapu S, Samsunder N, Garrett N, et al.
Sci Rep
. 2022 Feb;
12(1):2437.
PMID: 35165387
Previous studies have highlighted the role of pre-infection systemic inflammation on HIV acquisition risk, but the extent to which it predicts disease progression outcomes is less studied. Here we examined...
3.
Ismail S, Riou C, Joseph S, Archin N, Margolis D, Perelson A, et al.
Clin Infect Dis
. 2021 Jun;
73(8):1528-1531.
PMID: 34181706
Understanding what shapes the latent human immunodeficiency virus type 1 (HIV-1) reservoir is critical for developing strategies for cure. We measured frequency of persistent HIV-1 infection after 5 years of...
4.
Scheepers C, Bekker V, Anthony C, Richardson S, Oosthuysen B, Moyo T, et al.
Cell Rep
. 2020 Nov;
33(8):108430.
PMID: 33238131
Neutralizing antibodies (nAbs) to highly variable viral pathogens show remarkable diversification during infection, resulting in an "arms race" between virus and host. Studies of nAb lineages have shown how somatic...
5.
Molatlhegi R, Liebenberg L, Leslie A, Noel-Romas L, Mabhula A, Mchunu N, et al.
Mucosal Immunol
. 2020 Jan;
13(3):449-459.
PMID: 31896762
Long-acting injectable contraceptives have been associated with mucosal immune changes and increased HIV acquisition, but studies have often been hampered by the inaccuracy of self-reported data, unknown timing of injection,...
6.
Pacini C, Bradshaw C, Garrett N, Koziol M
Sci Rep
. 2019 Mar;
9(1):5185.
PMID: 30914725
A novel DNA modification, N-6 methylated deoxyadenosine (m6dA), has recently been discovered in eukaryotic genomes. Despite its low abundance in eukaryotes, m6dA is implicated in human diseases such as cancer....
7.
Tinarwo P, Zewotir T, Yende-Zuma N, Garrett N, North D
Infect Dis Ther
. 2019 Feb;
8(2):269-284.
PMID: 30756260
Introduction: Past endeavours to deal with the obstacle of expensive Cluster of Difference 4 (CD4) count diagnostics in resource-limited settings have left a long trail of suggested continuous CD4 count...
8.
Tanko R, Soares A, Masson L, Garrett N, Samsunder N, Abdool Karim Q, et al.
Clin Immunol
. 2018 Jun;
195:127-138.
PMID: 29883708
HIV infection results in excessive T cell activation and dysfunction which may persist even during effective antiretroviral therapy (ART). The dynamics of immune 'deactivation' and extent to which T cell...
9.
Garrett N, Osman F, Maharaj B, Naicker N, Gibbs A, Norman E, et al.
PLoS One
. 2018 Apr;
13(4):e0196209.
PMID: 29689080
Introduction: In light of the limited impact the syndromic management approach has had on the global sexually transmitted infection (STI) epidemic, we assessed a care model comprising point-of-care (POC) STI...
10.
Anthony C, York T, Bekker V, Matten D, Selhorst P, Ferreria R, et al.
J Virol
. 2018 Apr;
92(9).
PMID: 29654221
No abstract available.